Sunshine Biopharma Inc. Increase Decrease In Operating Lease Liability
Sunshine Biopharma Inc. (SBFM) reported Increase Decrease In Operating Lease Liability of -$105.27 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Sunshine Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$51.27K.
- Sunshine Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$54.00K.
- Sunshine Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$57.78K, a 113.26% decline year-over-year.
- Sunshine Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$54.20K.
- Sunshine Biopharma Inc. increase decrease in operating lease liability for fiscal 2025 was -$187.52K, a 153.90% decline from fiscal 2024.
- Sunshine Biopharma Inc. increase decrease in operating lease liability for fiscal 2024 was $347.94K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$51.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$105.27K 10-Q · filed 2026-08-13 | -$163.05K derived: sum of 3 quarters · filed 2026-08-13 | -$217.25K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$54.00K 10-Q · filed 2026-05-13 | -$111.78K derived: sum of 2 quarters · filed 2026-05-13 | -$165.99K derived: sum of 3 quarters · filed 2026-05-13 | -$224.36K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$57.78K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | -$111.99K derived: sum of 2 quarters · filed 2026-04-03 | -$170.36K derived: sum of 3 quarters · filed 2026-08-13 | -$187.52K 10-K · filed 2026-04-03 |
| 2025-09-30 | -$54.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$112.58K derived: sum of 2 quarters · filed 2026-08-13 | -$129.74K 10-Q · filed 2025-11-13 | $306.05K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$58.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$75.54K 10-Q · filed 2026-08-13 | $360.25K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$17.16K 10-Q · filed 2026-05-13 | $418.63K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $435.79K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $347.94K 10-K · filed 2026-04-03 | ||
| 2024-09-30 | -$87.85K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |